Investigational drug · Phase 2
PTP-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Osteoarthritis, Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "PTP-001"
First trial start
2021
Sep 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PTP-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteoarthritis, Knee
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "PTP-001" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)Pivotal-lookingRecruiting
Doron Therapeutics Inc.Industry
NCT07219771 · 300 participants (planned) · Start Oct 14, 2025 · Primary completion Jun 30, 2027
Drug: PTP-01 · For: Knee Osteoarthritis
Sites: Birmingham, Alabama; Tucson, Arizona; La Mesa, California · 18 sites in all
- Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee OsteoarthritisPivotal-lookingActive, not recruiting
Bioventus LLCIndustry
NCT05100225 · 210 participants (planned) · Start Sep 30, 2021 · Primary completion Oct 31, 2022
Drug: PTP-001 · For: Osteoarthritis, Knee
Sites: Botany, Australia; Broadmeadow, Australia; Saint Leonards, Australia · 14 sites in all
- Safety Study of PTP-001 for Treating Knee OsteoarthritisStatus unknown
Bioventus LLCIndustry
NCT04632966 · 20 participants · Start Feb 26, 2021 · Primary completion Sep 2022
Drug: Biological: PTP-001 · For: Knee Osteoarthritis
Sites: Durham, North Carolina; North Charleston, South Carolina
Newest research
PubMed records naming it or its code names, newest first.
- Composition and Bioactivity of a Placental Tissue Particulate (PTP-001) Indicate Greater Potential than Platelet-Rich Plasma for the Treatment of Osteoarthritis.
Flannery CR, Buddin KE, Begum L, et al. · Cartilage 2023
- A novel placental tissue biologic, PTP-001, inhibits inflammatory and catabolic responses in vitro and prevents pain and cartilage degeneration in a rat model of osteoarthritis.
Flannery CR, Seaman SA, Buddin KE, et al. · Osteoarthritis Cartilage 2021
Also in development for Osteoarthritis, Knee
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- matched to NNC0487-0111Phase 39 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- JOINTSTEMPhase 32 trials
R-Bio · Knee Osteoarthritis, Osteoarthritis, Knee
- LY4065967Phase 23 trials
Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
- AllocetraPhase 22 trials
Enlivex Therapeutics Ltd. · Primary Knee Osteoarthritis, Osteoarthritis, Knee
- PPV-06Phase 21 trial
Peptinov SAS · Osteoarthritis, Knee
- RHH646Phase 21 trial
Novartis · Osteoarthritis, Knee
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.